Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Wednesday

Edwards Lifesciences (NYSE:EW) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.60 per share and revenue of $1.40 billion for the quarter. Edwards Lifesciences has set its FY 2025 guidance at 2.400-2.500 EPS and its Q1 2025 guidance at 0.580-0.640 EPS.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts expect Edwards Lifesciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Trading Down 3.2 %

EW opened at $69.23 on Tuesday. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $95.25. The company has a fifty day moving average of $71.18 and a 200-day moving average of $70.95. The stock has a market cap of $40.70 billion, a PE ratio of 9.93, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Analysts Set New Price Targets

Several research analysts have recently weighed in on EW shares. Piper Sandler lifted their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Truist Financial dropped their price target on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. Evercore ISI cut their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Barclays increased their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and an average target price of $78.55.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the completion of the sale, the vice president now owns 47,206 shares in the company, valued at $3,295,450.86. This trade represents a 16.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bernard J. Zovighian sold 6,164 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at $4,106,859.33. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Edwards Lifesciences stock. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 3,587 shares of the medical research company’s stock, valued at approximately $266,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.